At its 2026 Annual Meeting of Stockholders, Allogene Therapeutics, Inc. stockholders' approved an amendment to the Certificate of Incorporation to increase the number of authorized shares from 400,000,000 to 800,000,000, effective June 18, 2026. Additionally, the company has filed a prospectus supplement to sell common stock with an aggregate offering price of up to $135.0 million. Allogene Therapeutics, Inc. is a biotechnology company focused on on-cell therapy.</div>